Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.03 by 266.67 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $10.11 million which missed the analyst consensus estimate of $21.60 million by 53.18 percent. This is a 169.82 percent increase over sales of $3.75 million the same period last year.